ADA 2026 featured incretin therapy advances, survodutide phase 3 data in metabolic liver disease, and cardiovascular risk reduction with evolocumab.
Lee Kaplan, MD, PhD
Advertisement
Lee Kaplan, MD, PhD, is the director of The Obesity and Metabolism Institute, Massachusetts General Hospital, in Boston, MA.
Articles by Lee Kaplan, MD, PhD
Survodutide Normalizes Liver Fat in 61% of Patients With MASLD in Phase 3 Trial: Lee Kaplan, MD, PhD
Phase 3 data show survodutide normalized liver fat in 61% of patients with MASLD while reducing weight, visceral fat, and metabolic risk factors.
ADA 2026 data show survodutide cut visceral fat by 34% and liver fat by 63%, suggesting metabolic benefits beyond weight loss in phase 3 trials.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes
2
Treatment Burden, End-of-Life Symptom Gaps in Multiple Myeloma
3
National HIV Testing Day Highlights Expanding PrEP, PEP Access, Persistent Barriers
4
Health Equity & Access Weekly Roundup: June 26, 2026
5